PARIS, May 17 (Reuters) - Sanofi said it would overhaul rather than exit its Toulouse research site, as it seeks to break an impasse with the French government which opposed the drugmaker's reorganisation plans and the loss of jobs.

PARIS, May 17 (Reuters) - French drugmaker Sanofi said a late-stage Phase III trial of a drug designed to treat myelofibrosis led to positive results.

Late-stage clinical trials begin for this duo's experimental rheumatoid arthritis drug.

Sanofi (NYSE: SNY) and Regeneron Pharmaceuticals, Inc.

PARIS, May 15 (Reuters) - French drugmaker Sanofi SA said it and U.S. firm Regeneron Pharmaceuticals have started recruiting patients for two new trials of their arthritis treatment sarilumab.

* Sanofi may appeal decision, shares down 0.6 percent (Adds details, Sanofi comments, shares)

PARIS, May 14 (Reuters) - French drugmaker Sanofi said on Tuesday it objected to a fine by the French Competition Authority in a dispute over generic competition to its blood thinner, Plavix, and said it was considering a possible appeal.

PARIS, May 14 (Reuters) - The French Competition Authority said on Tuesday it fined drugmaker Sanofi 40.6 million euros ($52.7 million) over what it called a smear campaign aimed at stifling generic competition to its blood thinner, Plavix.

European austerity measures and US patent expiries helped push first-quarter earnings at the French pharmaceutical group below consensus levels

Sanofi's business looks like a decent proxy for the future of the pharmaceutical sector. After years of slumping sales from pharmaceutical products, the worst at Sanofi is over.

PARIS, May 2 (Reuters) - Sanofi is stepping up the development of a fixed combination of diabetes treatments Lantus and Lyxumia to sidestep an earlier setback with a similar pen device and take advantage of the delayed U.S. launch of competitor Novo

European stock markets traded mostly lower on Thursday as markets await a potential rate cut from the ECB. Statoil, Sanofi and Infineon all react to results.

PARIS, May 2 (Reuters) - Sanofi SA : * opens 3.7 percent lower after Q1 results miss expectations

* Sees growth return in H2 (Adds emerging mrkt details, CEO, peers)

PARIS, May 2 (Reuters) - Sanofi reported lower-than-expected first-quarter earnings on Thursday as the effects of last year's patent losses damped growth from diabetes drugs, vaccines and rare disease unit Genzyme.

May 1 (Reuters) - Drugs from Amgen Inc, TevaPharmaceutical Industries and Sanofi thatboost white blood cells are being evaluated by U.S. regulatorsas treatments for radiation exposure caused by a nuclear attackor accident.

May 1 (Reuters) - Drugs from Amgen Inc, Teva Pharmaceutical Industries and Sanofi that boost white blood cells are being evaluated by U.S. regulators as treatments for radiation exposure caused by a nuclear attack or accident.

Linn Energy, Federated Investors, and Sanofi are on the list.

LONDON, April 26 (Reuters) - European regulators have recommended approval of two new cancer drugs, called Erivedge and Xtandi, from Roche and Astellas, underscoring a recent pick-up in novel treatments for the disease.

LONDON, April 26 (Reuters) - European regulators have recommended approval of two new cancer drugs, called Erivedge and Xtandi, from Roche and Astellas, underscoring a recent pick-up in novel treatments for the disease.

LONDON, April 26 (Reuters) - European regulators have recommended approval of two new cancer drugs, called Erivedge and Xtandi, from Roche and Astellas, underscoring a recent pick-up in novel treatments for the disease.

LONDON, April 26 (Reuters) - European regulators haverecommended approval of two new cancer drugs, called Erivedgeand Xtandi, from Roche and Astellas,underscoring a recent pick-up in novel...

LONDON, April 26 (Reuters) - European regulators have recommended approval of two new cancer drugs, called Erivedge and Xtandi, from Roche and Astellas.

Genzyme,a Sanofi company (NYSE: SNY), announced today positivetop-line results from the TOPIC trial for AUBAGIO (teriflunomide).

PARIS, April 22 (Reuters) - French drug maker Sanofi SA said on Monday the European Commission has approved its primary and booster vaccine for infants from six weeks of age.

By Peter Geschek:Among the largest vaccine makers, Merck (MRK), with a 2012 vaccine revenue of $5.27 billion, ranks second behind Sanofi (SNY) and just ahead of GlaxoSmithKline (GSK).GardasilMerck's best seller, the human papillomavirus (HPV) vaccine

Sanofi and Roche rally on a weaker FTSE Eurofirst 300 after brokers issue bullish notes on them, which boosts sentiment for other healthcare stocks

PARIS, April 11 (Reuters) - Sanofi said European authorities have agreed to review a marketing application for a new flu vaccine designed to combat the four strains of virus expected in the coming season.

Drug maker Sanofi has tried for over nine months to shut down a research lab in Toulouse, France. Employees staged protests and also found a strong ally.

Pieris AG and The Sanofi Group have jointly agreed to expand theirongoing discovery and development partnership to include a novelmultispecific Anticalin® program. Under the existing…

By ChinaBio Today: Deals and FinancingsSanofi SA (NYSE: SNY) is actively seeking China M&A opportunities in the consumer healthcare and veterinary products sectors, according to the company's CEO, Christopher Viehbacher, who was quoted in a Wall Str

Sanofi expects to see double-digit growth in China in the coming five years, as the French drug company plans to expand its animal health and vaccine business in the country.

Sanofi

Sanofi

Sanofi

This morning First Read brings you the truth about private equity and hedge funds; Sanofi seeking more VC deals and an analysis on the internationalization of high tech start-ups.The post peHUB First Read appeared first on peHUB.

By EP Vantage:Thanks to a European regulatory verdict, the golden age of oral multiple sclerosis medications might be short-lived in the region. The European Medicines Agency's vote in support of Aubagio came with a surprise judgement that the Sanofi

Sanofi (NYSE: SNY) and Transgene announced today a collaboration agreement for thecreation of a new state-of-the-art industrial platform dedicated to theproduction of immunotherapy products including Transgene's therapeuticproducts.

LONDON, March 25 (Reuters) - Uncertainty over European exclusivity for Sanofi's new multiple sclerosis (MS) pill Aubagio could disrupt the wider market and impact other companies, according to a...

LONDON, March 25 (Reuters) - Uncertainty over European exclusivity for Sanofi's new multiple sclerosis (MS) pill Aubagio could disrupt the wider market and impact other companies, according to a leading industry analyst.

LONDON, March 25 (Reuters) - Uncertainty over European exclusivity for Sanofi's new multiple sclerosis (MS) pill Aubagio could disrupt the wider market and impact other companies, according to a leading industry analyst.

LONDON, March 25 (Reuters) - Uncertainty over Europeanexclusivity for Sanofi's new multiple sclerosis (MS)pill Aubagio could disrupt the wider market and impact othercompanies, according to a...

MS drug is awaiting regulatory response in the U.S. and Europe.

LONDON, March 22 - New multiple sclerosis drugs from BiogenIdec and Sanofi have been recommended forapproval in Europe.

Boeing and Raytheon, UTC, IBM, and even Sanofi walk away richer.